New assay for DRG:HYBRiD-XL®: PSA
DRG is proud to announce the launch of another tumor marker assay
for DRG:HYBRiD-XL®: PSA, REF: HYE-5370!
DRG´s assay is for the measurement of total Prostate-specific Antigen concentration (t-PSA) in serum or plasma (EDTA-, heparin- or citrate plasma).
Clinical Application:
- Estimation risk of prostate carcinoma in men in conjunction with digital rectal examination (DRE)
- Monitor effectiveness of prostate carcinoma treatment
Clear advantages of HYE-5370:
- Very good correlation to Roche cobas (r = 0.995)
- Good sensitivity
- Clinical significance of results highly comparable with market leaders
- Completely automated
- Two controls included
- Two re-calibrators included
- CE (certified by notified body #0197)
You may order with the following catalog number:
- PSA (HYE-5370)
